Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 32INDUSTRY 5NIH 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 481Neoplasms 294Breast Neoplasms 282Colorectal Neoplasms 225Neoplasm Metastasis 191Prostatic Neoplasms 172Ovarian Neoplasms 165Lung Neoplasms 155Multiple Myeloma 153Recurrence 133Melanoma 117Pancreatic Neoplasms 114Squamous Cell Carcinoma of Head and Neck 105Stomach Neoplasms 98Endometrial Neoplasms 98Leukemia, Myeloid, Acute 96Small Cell Lung Carcinoma 85Leukemia, Lymphocytic, Chronic, B-Cell 83Lymphoma, Non-Hodgkin 82Triple Negative Breast Neoplasms 81Carcinoma, Renal Cell 81Carcinoma, Hepatocellular 80Urinary Bladder Neoplasms 75Lymphoma, Large B-Cell, Diffuse 73Lymphoma, Follicular 67Advanced Solid Tumors 64Lymphoma 62Glioblastoma 60Parkinson Disease 4, Autosomal Dominant Lewy Body 56Head and Neck Neoplasms 54

Interventions

blinatumomab 2tisagenlecleucel 1fludarabine phosphate 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm, Residual × 90 days × Clear all
NCT05232916 2026-06-04

FLAMINGO-01

Greenwich LifeSciences, Inc.

Phase 3 Recruiting
750 enrolled
Breast

Breast Neoplasms, Neoplasm, Residual

NCT03876769 2026-06-02

CASSIOPEIA

Novartis

Phase 2 Active not recruiting
121 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

NCT06500273 2026-06-02

ALPHA3

Allogene Therapeutics

Phase 2 Recruiting
250 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT04521231 2026-05-28

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Amgen

Phase 1/2 Active not recruiting
181 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07134088 2026-05-15

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Amgen

Phase 1/2 Active not recruiting
104 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡